STAT+: Virginia governor vetoes plans to create a prescription drug affordability board
Virginia Gov. Glenn Youngkin vetoed a bill that would have created a new entity for…
Category: Medicine
.jpg)
STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost
In the latest gambit to lower the cost of a pricey medicine, three advocacy groups…
STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: MassMutual is rolling out free genetic testing for members, a dicey area for life insurers
One of the country’s biggest life insurers is venturing into genetic testing, an area that’s…
Pfizer’s plot to win the RSV vaccine race
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotech startups post strongest financing numbers in two years
The numbers are in, and biotech startups recently closed out their best fundraising quarter in…
After years of just ‘running, running,’ a crisis led to a lupus diagnosis. Now she connects others
Teenagers don’t get arthritis. That’s what Tiffany Peterson kept hearing as that dreadful feeling in…
Opinion: As a rule, rape exceptions for abortion don’t work
A year before the Supreme Court overturned Roe v. Wade in 2022, Texas implemented Senate…
STAT+: Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells
The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on…
Medicaid redetermination cost community health centers an average of $600K each
It’s been a year since states began the process of Medicaid redetermination, going through their…
STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study
A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave…
HCA’s charity care filings are on hyperdrive
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
STAT+: New liquid biopsy screening test for pancreatic cancer shows promise in early data
For the vast majority of pancreatic cancer cases, the tumor grows undetected until it has…
The latest updates on cancer research from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on
File this under “Not a moment too soon.” After years of back-and-forth deliberations, the U.S….
Patient with transplanted pig kidney had a ‘tense’ rejection episode before leaving the hospital
The world’s first recipient of a kidney transplant from a genetically modified pig experienced a…
Opinion: The time has come for over-the-counter antidepressants
Anyone can now walk into a pharmacy in the United States and buy oral contraceptives…
STAT+: HCA reports almost $1 billion more in charity care to Medicare than to its shareholders, drawing more taxpayer money
The country’s biggest hospital chain, HCA Healthcare, told the Centers for Medicare and Medicaid Services…
STAT+: WHO scientists question Grail’s plan for evaluating its multi-cancer Galleri blood test
A new analysis published Sunday challenges the clinical trial endpoint the cancer screening firm Grail…
STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life
SAN DIEGO — For decades, the Food and Drug Administration’s accelerated approval pathway has helped…
STAT+: Cancer is rising among the young. Study suggests it’s because their cells are aging faster
SAN DIEGO — Cancer cases among younger people have been rising for years, a trend…
STAT+: In first big randomized trial, Abiomed’s heart pump reduced deaths in heart attack patients
A controversial heart pump from Abiomed reduced the number of deaths in severe heart attack…
Large trial challenges common practice of prescribing beta blockers after heart attack
ATLANTA — Beta blockers are a mainstay in cardiovascular treatment, frequently given to patients after…
.jpg)
STAT+: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills
ATLANTA — New trial results show that a drug candidate from Alnylam Pharmaceuticals can lead…
STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure
ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity,…
Opinion: STAT readers on biotech and national security, liquid-only diets before colonoscopy, and the value of weight loss drugs
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
CDC to doctors: Look out for bird flu infections among dairy farm workers
The Centers for Disease Control and Prevention urged medical practitioners on Friday to be on…
STAT+: Teladoc CEO Jason Gorevic to leave the company
In a decision that surprised Wall Street analysts, Teladoc Health announced that long-time CEO Jason…
STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
Sanofi resolves most Zantac litigation
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Johnson & Johnson to buy Shockwave Medical for $13.1 billion
Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for…
Your dog is probably on Prozac. Experts say that says more about the American mental health crisis than pets
Dogs, our sunny, selfless shadows, crave little more than a daily walk, a treat or…
Why a leading bird flu expert isn’t convinced that the risk H5N1 poses to people has declined
News that H5N1 avian influenza has breached another mammalian species — this time dairy cows…
Opinion: Personalized medicine: We’re not there yet
When Francis Collins, then-director of the National Human Genome Research Institute, testified before Congress in…
Opinion: Does addiction make you un-American?
Should Prince Harry be deported from the United States due to his past drug use?…
Baylor wins 2024 STAT Madness with ‘smoke alarm’ for viral disease outbreaks
It began with injecting monkeys with sewage to see if they developed polio. Building off…
STAT+: Nuclear Regulatory Commission advisers beset by conflicts of interest, report finds
The oversight division of a U.S. government agency tasked with ensuring the safe use of…
STAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar…
Federal judge rules against Philadelphia supervised drug consumption effort
A federal judge this week dealt a major and likely decisive blow to Safehouse, a…
Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Why is it surprising when drug executives stay true to their word? And can neoantigen…
Why very few people who are eligible for a cochlear implant actually get one
Cochlear implants have successfully improved hearing loss for decades, but few people who qualify for…
Opinion: How climate change is driving a global epidemic of immune health problems, and how to stop it
Many of the effects of climate change play out at a very large scale: Heatwaves…
STAT+: Weed for weight loss, and more from Biotech Land
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
Health tech investor Glen Tullman launches 62 Ventures, a new $100 million fund
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
How resurrecting extinct species might impact medicine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise
On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after…
STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more
Top of the morning to you, and a fine one it is. After two days…
STAT+: Amylyx to pull ALS drug from market, cut 70% of staff
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and…
What ‘de-extinction’ of woolly mammoths can teach us: a Q&A with evolutionary biologist Beth Shapiro
Humans have long tinkered with the evolutionary trajectories of other species. Thousands of years ago…